RSS Almirall http://www.almirall.com Web Corporativa Almirall 2.0 <![CDATA[ Almirall begins the transformation ]]> <![CDATA[ Almirall maintains its shareholder return thanks to its R&D and internationalisation results ]]> <![CDATA[ Almirall and Forest Laboratories announce positive results for the second Phase III study for aclidinium and formoterol combination in COPD ]]> <![CDATA[ Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD ]]> <![CDATA[ Almirall presents the latest news in respiratory diseases ]]> <![CDATA[ Coordination among professionals is crucial for good vascular patient care ]]> <![CDATA[ Almirall commercialises Neurofarmagen, an innovative genetic test ]]> <![CDATA[ Eklira® Genuair® by Almirall available in Spain for the treatment of COPD ]]> <![CDATA[ Almirall celebrates 10 years in Italy ]]> <![CDATA[ Almirall and Forest Laboratories announce commercial availability of Tudorza™ Pressair™ in U.S. pharmacies ]]> <![CDATA[ Constella® (linaclotide) approved in Europe for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults ]]> <![CDATA[ Almirall appoints Karin Louise Dorrepaal as new independent board member ]]> <![CDATA[ 3rd Quarter Results ]]> <![CDATA[ Low awareness of chronic obstructive pulmonary disease (COPD) confirmed in a recent survey ]]> <![CDATA[ Almirall invests in personalised medicine by becoming part of the share capital of AB-Biotics ]]> <![CDATA[ Almirall incorporates Gerhard Mayr to the Board of Directors ]]> <![CDATA[ Sativex® confirms clinically relevant benefits in Multiple Sclerosis Spasticity ]]> <![CDATA[ Almirall licenses Aclidinium to Invida in Australia and ]]> <![CDATA[ Linaclotide receives positive CHMP opinion for the treatment of IBS-C ]]> <![CDATA[ Almirall launches Eklira® Genuair® (aclidinium) in Europe ]]> <![CDATA[ Almirall obtains rights for Linaclotide in Mexico ]]> <![CDATA[ Almirall opens a new affiliate in Canada ]]> <![CDATA[ Eklira® Genuair® provides meaningful and sustained bronchodilation from the first dose. Patients prefer the Genuair® inhaler over HandiHaler® ]]> <![CDATA[ Almirall's H1: Strong newsflow and guidance reiterated ]]> <![CDATA[ Almirall and Forest Laboratories announce FDA approval of Tudorza™ Pressair™ for the long-term maintenance treatment of COPD ]]> <![CDATA[ Eklira®/Bretaris® Genuair® (aclidinium bromide) approved in Europe for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) ]]> <![CDATA[ ¿Qué medicamentos tendrán nuestros hijos? Retos para equilibrar investigación y coste sanitario (only available in spanish) ]]> <![CDATA[ Abediterol, Almirall's OD LABA shows superiority vs indacaterol in Phase IIa ]]> <![CDATA[ Almirall's aclidinium recommended for approval in Europe to treat COPD ]]> <![CDATA[ Almirall and ASLAN sign a global agreement on a novel treatment for Rheumatoid Arthritis ]]>